Led · Series C · Jul 2026

CoreMap develops a proprietary electrophysiology mapping system that combines high-density electrical data acquisition with sophisticated analytical software to generate detailed electrical activation maps of atrial fibrillation. The platform is designed to help electrophysiologists identify arrhythmia sources more accurately during catheter ablation procedures. CoreMap plans to use the new capital to accelerate product development and move the technology closer to commercial availability. The company believes improved mapping can address persistent clinical challenges in AF treatment and support more targeted procedural decision-making. Founded in 2016 and headquartered in Burlington, Massachusetts, CoreMap is positioning itself to compete in the expanding electrophysiology market with strategic backing from Medtronic following the Series C financing.

Led · Series B · Jul 2026

RapidPulse is developing a pulsed (cyclic) aspiration platform and a range of catheter sizes intended to improve clot engagement, removal efficiency and procedural consistency during mechanical thrombectomy for acute ischemic stroke. The company’s system is being evaluated in the TURBO investigational device exemption study, conducted in the United States and Europe to support its U.S. regulatory pathway. RapidPulse plans to expand clinical experience with its system across leading stroke centers as part of that program and may pursue FDA approval if clinical data support a submission. The platform strategy includes continued development of the catheter portfolio and broader clinical use to gather performance data across different patients, clot types and treatment settings. RapidPulse was spun out of medical device incubator Syntheon and is headquartered in Miami. Financially, the company recently raised an oversubscribed $48 million Series B co-led by Medtronic, TechWald Next and S3 Ventures, with additional participation from SBI Investment Company, the Florida Opportunity Fund, and existing investors.

Participated · Series C · Jun 2026

CereVasc is a clinical-stage medical device company based in Massachusetts developing the eShunt System, an investigational, patented endovascularly implantable cerebrospinal fluid shunt and delivery components. The eShunt employs a percutaneous transvenous-transdural approach intended to enable a minimally invasive treatment for communicating hydrocephalus. The company is currently conducting the STRIDE pivotal trial, a prospective, multi-center, randomized, controlled study comparing the eShunt System to the standard ventriculo-peritoneal (VP) shunt to evaluate safety and effectiveness. Data from STRIDE are intended to support a future FDA Premarket Approval (PMA) submission. CereVasc describes the eShunt as investigational and not yet approved for commercial sale. The company plans to use recent Series C proceeds to complete the pivotal trial, advance regulatory work, scale operations, and prepare for U.S. commercialization.

Led · Series D · Apr 2026

Pulnovo Medical develops a Pulmonary Artery Denervation (PADN) system, a minimally invasive interventional therapy targeting over‑activated sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. Multiple global studies and inclusion in international guidelines (including the 2022 ESC/ERS Guidelines) support PADN’s clinical benefits in improving functional capacity and reducing major adverse events. The company reports approximately 1,500 PADN procedures performed globally and regulatory approvals in seven countries, while actively promoting commercialization in the EU, Middle East, and China. In the U.S., Pulnovo has received FDA Breakthrough Device Designation and launched two fully approved IDE clinical trials led by Professor Gregg Stone. Pulnovo is pursuing further clinical evidence (including the PULSE‑LHD IDE trial) and is expanding its global clinical, regulatory, and commercial footprint, including a commercial cooperation agreement with Medtronic. The recent financing will fund continued clinical R&D, global regulatory filings, international commercialization, and investment in the core technology platform.

Led · Equity · Apr 2026

Pulnovo Medical develops a proprietary Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy aimed at modulating sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. The company reports about 1,500 PADN procedures performed globally and regulatory approvals in seven countries, and it is advancing commercialization across the European Union, Middle East, and China. Pulnovo's therapy has been referenced in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines, and clinical studies are ongoing in Europe and Asia with U.S. IDE trials recently initiated. In the United States the company has received FDA Breakthrough Device designation and has started two fully approved IDE trials, including the PULSE-LHD trial. Following the $100 million strategic financing led by Medtronic, Pulnovo plans to use proceeds to support clinical development, regulatory submissions, international commercialization, and continued technology investment. The company is also expanding its leadership team, hiring a Chief Strategy Officer to strengthen ties with global capital markets and industry partners.